New process for the synthesis of UP 269-6, a 1,2,4-triazolo[1,5-c]pyrimidine derivative as a potent orally active angiotensin II antagonist

Article abstract of DOI:10.1002/jhet.5570330450

A new synthetic route to prepare the 2-hydroxy-5-methyl-7-n-propyl-8-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]m ethyl]-[1,2,4]triazolo[1,5-c]pyrimidine (UP 269-6, Ripisartan) is described. UP 269-6 is a non-peptide angiotensin II antagonist currently in phase